Comparative in vitro activity of gemifloxacin against gram-positive and gram-negative clinical isolates in ArgentinaLOPEZ, H; STEPANIK, D; VILCHES, V et al.Diagnostic microbiology and infectious disease. 2001, Vol 40, Num 4, pp 187-192, issn 0732-8893Article

Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniaeOWENS, Robert C; BHAVNANI, Sujata M; AMBROSE, Paul G et al.Diagnostic microbiology and infectious disease. 2005, Vol 51, Num 1, pp 45-49, issn 0732-8893, 5 p.Article

Effect of calcium carbonate on bioavailability of orally administered gemifloxacinPLETZ, M. W; PETZOLD, P; ALLEN, A et al.Antimicrobial agents and chemotherapy. 2003, Vol 47, Num 7, pp 2158-2160, issn 0066-4804, 3 p.Article

Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panelsROSS, James E; SADER, Helio S; FRITSCHE, Thomas R et al.Diagnostic microbiology and infectious disease. 2005, Vol 51, Num 3, pp 219-221, issn 0732-8893, 3 p.Article

Comparative Study of the Mutant Prevention Concentrations of Moxifloxacin, Levofloxacin, and Gemifloxacin against PneumococciCREDITO, Kim; KOSOWSKA-SHICK, Klaudia; MCGHEE, Pamela et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 2, pp 673-677, issn 0066-4804, 5 p.Article

Gemifloxacin for the management of community-acquired respiratory tract infectionsBLONDEAU, J. M; TILLOTSON, G; DEANGELIS, J et al.Journal of chemotherapy. 2006, Vol 18, Num 6, pp 582-588, issn 1120-009X, 7 p.Article

13 -Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents = Antibiothérapie des pneumonies aiguës communautaires (PAC) dues a des agents atypiquesROIG, J; CASAL, J; GISPERT, P et al.Médecine et maladies infectieuses. 2006, Vol 36, Num 11-12, pp 680-689, issn 0399-077X, 10 p.Conference Paper

Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniaeSARAVOLATZ, Louis; MANZOR, Odette; PAWLAK, Joan et al.International journal of antimicrobial agents. 2005, Vol 26, Num 1, pp 81-84, issn 0924-8579, 4 p.Article

Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal originLEOPHONTE, P; FILE, T; FELDMAN, C et al.Respiratory medicine. 2004, Vol 98, Num 8, pp 708-720, issn 0954-6111, 13 p.Article

Synthesis of carbon-14 labelled gemifloxacinHYUN IL SHIN; JONG GILL RIM; KI SEUNG LEE et al.Journal of labelled compounds & radiopharmaceuticals. 2004, Vol 47, Num 11, pp 779-786, issn 0362-4803, 8 p.Article

Gemifloxacin: effects of sub-inhibitory concentrations on various factors affecting bacterial virulenceDAL SASSO, M; CULICI, M; BOVIO, C et al.International journal of antimicrobial agents. 2003, Vol 21, Num 4, pp 325-333, issn 0924-8579, 9 p.Article

Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (synercid) compared to its susceptibilities to reference macrolides and quinolonesBRABÄCK, Martin; RIESBECK, Kristian; FORSGREN, Arne et al.Antimicrobial agents and chemotherapy. 2002, Vol 46, Num 4, pp 1114-1116, issn 0066-4804Article

Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistanceBOSWELL, F. J; ANDREWS, J. M; JEVONS, G et al.Journal of antimicrobial chemotherapy (Print). 2002, Vol 50, Num 4, pp 495-502, issn 0305-7453, 8 p.Article

Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: A randomized, open-label, multicenter study of clinical efficacy and tolerabilityLODE, Hartmut; FILE, Thomas M; MANDELL, Lionel et al.Clinical therapeutics. 2002, Vol 24, Num 11, pp 1915-1936, issn 0149-2918, 22 p.Article

Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic modelPORTNOY, Yury A; VOSTROV, Sergey N; LUBENKO, Irene Yu et al.International journal of antimicrobial agents. 2002, Vol 20, Num 3, pp 201-205, issn 0924-8579, 5 p.Article

Comparative in vitro activities of five quinolone antibiotics, including gemifloxacin, against clinical isolatesGÖNÜLLÜ, N; AKTAS, Z; SALCIOGLU, M et al.Clinical microbiology and infection. 2001, Vol 7, Num 9, pp 499-503, issn 1198-743XArticle

Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance studyHOBAN, D. J; BOUCHILLON, S. K; JOHNSON, J. L et al.European journal of clinical microbiology & infectious diseases (Print). 2001, Vol 20, Num 11, pp 814-819, issn 0934-9723Article

Competitive Inhibition of Renal Tubular Secretion of Gemifloxacin by ProbenecidLANDERSDORFER, Cornelia B; KIRKPATRICK, Carl M. J; KINZIG, Martina et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 9, pp 3902-3907, issn 0066-4804, 6 p.Article

HPLC of fluoroquinolone antibacterials using chiral stationary phase based on enantiomeric (3,3'-diphenyl-1,1'-binaphthyl)-20-crown-6HEE JUNG CHOI; HWAN SUN CHO; SANG CHEOL HAN et al.Journal of separation science (Print). 2009, Vol 32, Num 4, pp 536-541, issn 1615-9306, 6 p.Article

Validated Stability Indicating Assay of Gemifloxacin and Lomefloxacin in Tablet Formulations by Capillary ElectrophoresisELBASHIR, Abdalla A; SAAD, Bahruddin; ABDUSSALAM SALHIN MOHAMED ALI et al.Journal of liquid chromatography & related technologies. 2008, Vol 31, Num 9-12, pp 1465-1477, issn 1082-6076, 13 p.Article

Fluoroquinolone resistance in Streptococcus pneumoniae : Area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacinLAPLANTE, Kerry L; RYBAK, Michael J; TSUJI, Brian et al.Antimicrobial agents and chemotherapy. 2007, Vol 51, Num 4, pp 1315-1320, issn 0066-4804, 6 p.Article

Synthesis and antibacterial activity of novel fluoroquinolones containing substituted piperidinesZHAO DANG; YUSHE YANG; RUYUN JI et al.Bioorganic & medicinal chemistry letters (Print). 2007, Vol 17, Num 16, pp 4523-4526, issn 0960-894X, 4 p.Article

Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolonesBLONDEAU, J. M; BLONDEAU, L. D; HESJE, C et al.Journal of chemotherapy. 2006, Vol 18, Num 4, pp 366-372, issn 1120-009X, 7 p.Article

Cutaneous adverse events and gemifloxacin : Observations from the clinical trial programIANNINI, P; MANDELL, L; PATOU, G et al.Journal of chemotherapy. 2006, Vol 18, Num 1, pp 3-11, issn 1120-009X, 9 p.Article

Geographically-based evaluation of multidrug resistance trends among Streptococcus pneumoniae in the USA: findings of the FAST surveillance initiative (2003-2004)DRAGHI, D. C; JONES, M. E; SAHM, D. F et al.International journal of antimicrobial agents. 2006, Vol 28, Num 6, pp 525-531, issn 0924-8579, 7 p.Article